Clinically, SIGLEC8 may play a role in preventing chronic lung inflammation in asthma by inducing cell death of activated eosinophils, supported by the observation that polymorphisms have been associated with asthma susceptibility in humans (55, 56). Here, SIGLEC8 is linked to asthma.